<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166997</url>
  </required_header>
  <id_info>
    <org_study_id>EKOS Protocol Number 08</org_study_id>
    <nct_id>NCT01166997</nct_id>
  </id_info>
  <brief_title>ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism</brief_title>
  <acronym>ULTIMA</acronym>
  <official_title>Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EKOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EKOS Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right
      ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV
      ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as
      compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio
      will be significantly reduced in the treatment arm compared to the control arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of RV/LV Ratio</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in the end-diastolic RV/LV ratio from baseline to 24 hours by echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding and Intracranial Bleeding at 30 Days.</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding will be classified as major if it is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal). To aid in evaluating the relationship of bleeding events to rt-PA administration, they will also be categorized by whether they occurred within 3 days after the initiation of thrombolytic therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Submassive Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Ultrasound accelerated thrombolysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous unfractionated heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EkoSonic Endovascular System</intervention_name>
    <description>The EkoSonic Endovascular System will be used to deliver &lt; 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.</description>
    <arm_group_label>Ultrasound accelerated thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>Intravenous unfractionated heparin used for anticoagulation treatment</description>
    <arm_group_label>Intravenous unfractionated heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute PE symptoms &lt; 14 days.

          -  Filling defect by contrast-enhanced chest CT in at least one main or proximal lower
             lobe pulmonary artery

          -  Right ventricular dysfunction confirmed by echocardiography where the RV/LV end
             diastolic diameter ratio is ≥ 1.0.

        Exclusion Criteria:

          -  Age less than 18 years or greater than 80 years

          -  Index PE symptom duration &gt; 14 days

          -  Insufficient echocardiographic image quality in the apical or subcostal four-chamber
             view that prohibits the measurement of the right and left ventricular end-diastolic
             dimensions

          -  Known significant bleeding risk

          -  Administration of thrombolytic agents, e.g., tissue plasminogen activator,
             streptokinase, or urokinase, within the previous 4 days

          -  Active bleeding

          -  Known bleeding diathesis

          -  Known coagulation disorder, platelet count &lt; 100 000/mm3, or previous use of vitamin K
             antagonists with INR &gt; 2.5

          -  History of any intracranial or intraspinal surgery or trauma or
             intracranial/intraspinal bleed

          -  Intracranial neoplasm, arteriovenous malformation, or aneurysm

          -  Recent (&lt; 3 months) GI bleeding.

          -  Recent (&lt; 3 months) internal eye surgery or hemorrhagic retinopathy; recent (&lt; 10
             days) major surgery, cataract surgery, trauma, CPR, obstetrical delivery, or other
             invasive procedure.

          -  Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated
             contrast, except for mild-moderate contrast allergies for which steroid pre-medication
             can be used.

          -  Estimated glomerular filtration rate (eGFR) &lt; 50 ml/min as calculated by the Cockroft
             formula.

          -  Hemodynamic collapse at presentation defined as: need for cardiopulmonary
             resuscitation; or systolic blood pressure &lt; 90 mm Hg for at least 15 min, or drop of
             systolic blood pressure by at least 40 mm Hg for at least 15 min with signs of end
             organ hypoperfusion (cold extremities or low urinary output &lt; 30 mL/h or mental
             confusion); or need for catecholamine administration to maintain adequate organ
             perfusion and a systolic blood pressure of &gt; 90 mm Hg.

          -  Severe hypertension on repeated readings (systolic &gt; 180 mmHg or diastolic &gt; 105
             mmHg).

          -  Pregnant, lactation or parturition within the previous 30 days (positive pregnancy
             test, women of childbearing age must be tested).

          -  Participating in any other investigational drug or device study.

          -  Life expectancy &lt; 90 days.

          -  Inability to comply with study assessments (e.g. due to geographic distance).

          -  Previous enrollment in this study

          -  Any other condition that the investigator feels would place the patient at increased
             risk if the investigational therapy is initiated.

          -  Known right-to-left shunt, for example from large patent foramen ovale or atrial
             septal defect

          -  Large (&gt;10 mm) right atrial or right ventricular thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Kucher, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern, Kliniken für Angiologie und Kardiologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Lippe-Detmold</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Ernst-Moritz-Arndt-Universität,</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilians-Universität (LMU)</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christliches Krankenhaus Quakenbrueck</name>
      <address>
        <city>Quakenbrueck</city>
        <zip>49610</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Zentralklinikum Suhl</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern, Kliniken fur Kardiologie and Angiologie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <results_first_submitted>August 23, 2016</results_first_submitted>
  <results_first_submitted_qc>August 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2016</results_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Pulmonary thromboembolism</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>ultrasound accelerated thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multi-center, Phase III study at 8 tertiary care hospitals in Germany and Switzerland</recruitment_details>
      <pre_assignment_details>Acute symptomatic PE confirmed by contrast-enhanced computed tomography (CT) with embolus located in at least 1 main or proximal lower lobe pulmonary artery RV to left ventricular dimension (RV/LV) ratio ≥1 obtained from the echocardiographic apical 4-chamber view</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Unfractionated Heparin (UFH) Alone</title>
          <description>Patients in this arm received the standard of care: intravenous unfractionated heparin used as anticoagulation treatment.</description>
        </group>
        <group group_id="P2">
          <title>Unfractionated Heparin (UFH) + EkoSonic Procedure</title>
          <description>Patients in this arm received anticoagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System was used to deliver a low dose of &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UFH (Alone)</title>
          <description>Patients in this arm received the standard of care: intravenous unfractionated heparin used as anticoagulation treatment.</description>
        </group>
        <group group_id="B2">
          <title>UFH + EkoSonic Procedure</title>
          <description>Patients in this arm received anticoagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System was used to deliver a low dose of &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="13.4"/>
                    <measurement group_id="B2" value="64.1" spread="15.2"/>
                    <measurement group_id="B3" value="63.1" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of RV/LV Ratio</title>
        <description>Change in the end-diastolic RV/LV ratio from baseline to 24 hours by echocardiography.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unfractionated Heparin (UFH) Alone</title>
            <description>Patients in this arm received the standard of care: intravenous unfractionated heparin used as anticoagulation treatment.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heprin + EkoSonic Procedure</title>
            <description>Patients in this arm received anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System was used to deliver a low dose of &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of RV/LV Ratio</title>
          <description>Change in the end-diastolic RV/LV ratio from baseline to 24 hours by echocardiography.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="0.30" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding and Intracranial Bleeding at 30 Days.</title>
        <description>Bleeding will be classified as major if it is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal). To aid in evaluating the relationship of bleeding events to rt-PA administration, they will also be categorized by whether they occurred within 3 days after the initiation of thrombolytic therapy.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrasound Accelerated Thrombolysis</title>
            <description>Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
EkoSonic Endovascular System: The EkoSonic Endovascular System will be used to deliver &lt; 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Unfractionated Heparin</title>
            <description>Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
Unfractionated heparin: Intravenous unfractionated heparin used for anticoagulation treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding and Intracranial Bleeding at 30 Days.</title>
          <description>Bleeding will be classified as major if it is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal). To aid in evaluating the relationship of bleeding events to rt-PA administration, they will also be categorized by whether they occurred within 3 days after the initiation of thrombolytic therapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Unfractionated Heparin (UFH) Alone</title>
          <description>Patients in this arm received the standard of care: intravenous unfractionated heparin used as anticoagulation treatment.</description>
        </group>
        <group group_id="E2">
          <title>UFH + EkoSonic</title>
          <description>Patients in this arm received anticoagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System was used to deliver a low dose of &lt;20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Allen</name_or_title>
      <organization>EKOS Corporation</organization>
      <phone>4254153100</phone>
      <email>Lynn.Allen@ekoscorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

